- Report
- October 2024
- 196 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- January 2025
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- October 2024
- 184 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- April 2024
- 279 Pages
Global
From €3340EUR$3,500USD£2,799GBP
€4772EUR$5,000USD£3,998GBP
- Report
- March 2025
- 293 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- January 2025
- 139 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- April 2024
- 135 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- August 2024
- 200 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Drug Pipelines
- April 2024
- 150 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- May 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- November 2023
- 312 Pages
Global
From €5374EUR$5,827USD£4,350GBP
- Report
- June 2023
- 308 Pages
Global
From €4879EUR$5,292USD£3,950GBP
- Report
- December 2021
- 353 Pages
Global
From €2625EUR$2,750USD£2,199GBP
€5249EUR$5,500USD£4,398GBP
- Report
- September 2021
- 258 Pages
Global
From €2625EUR$2,750USD£2,199GBP
€5249EUR$5,500USD£4,398GBP
- Report
- May 2023
- 120 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- February 2024
- 250 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- March 2024
- 138 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Clinical Trials
- August 2022
- 150 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- July 2021
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- February 2024
- 169 Pages
Global
From €2386EUR$2,500USD£1,999GBP

The Cancer Biologics market is a subset of the larger Biotechnology industry. It focuses on the development and commercialization of biologic drugs for the treatment of cancer. These drugs are typically derived from living organisms, such as proteins, antibodies, and other molecules, and are used to target and treat cancer cells. They are often used in combination with other treatments, such as chemotherapy and radiation therapy, to improve outcomes.
Cancer biologics are typically developed through a combination of laboratory research, clinical trials, and regulatory approval. Companies in this market are typically involved in the research, development, manufacturing, and marketing of these drugs.
Notable companies in the Cancer Biologics market include Amgen, Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche. Show Less Read more